The FDA has granted accelerated approval for the elamipretide injection, the first treatment for Barth syndrome in patients weighing at least 30 kg.
Barth syndrome is a life threatening disease of the mitochondria. The injection works by binding the inner part of the mitochondria to enhance both its structure and function, according to a Sept. 19 news release from the agency. The FDA granted the injection accelerated approval, a regulatory pathway that allows earlier access to treatments for serious conditions that address an unmet medical need.
The approval is based on a measure that showed improved strength for the muscle used to strengthen the leg at the knee.
As a condition of the accelerated approval, the agency is requiring the drug manufacturer to conduct a post-approval randomized, double-blind, placebo-controlled trial on the changes seen on knee muscle strength, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
